Julian Adams

Julian Adams currently works at Stand Up To Cancer, as President & Chief Executive Officer from 2023, Elicio Therapeutics, Inc., as Independent Chairman from 2017, and Princess Margaret Cancer Foundation, as Director from 2014.
Dr. Adams also formerly worked at Elicio Therapeutics, Inc. (United States), as Chairman from 2017 to 2023, Rein Therapeutics, Inc., as Director from 2011 to 2013, ProScript, Inc., as Director, Executive VP-Research & Development, Boehringer Ingelheim Corp., as Director-Medicinal Chemistry, Predix Pharmaceuticals Holdings, Inc., as Director, CureTech Ltd., as Director, Warp Drive Bio, Inc., as Director, Pieris Pharmaceuticals, Inc., as Independent Director from 2016 to 2018, BioNTech US, Inc., as Independent Director from 2017 to 2018, Gamida Cell Ltd., as Independent Director from 2022 to 2024, Merck & Co., Inc., as Medicinal Chemist from 1982 to 1987, Millennium Pharmaceuticals, Inc., as Senior Vice President-Drug Discovery & Development from 1999 to 2003, LeukoSite, Inc., as Senior Vice President-Research & Development in 1999, Clal Biotechnology Industries Ltd., as President & Chief Science Officer in 2017, Infinity Pharmaceuticals, Inc., as President-Research & Development from 2011 to 2017, Limulus Management Co. LLC, as Advisor, Clal Biotechnology Industries Ltd. (Venture Capital), as President & Chief Science Officer, and Infinity Discovery, Inc., as President in 2006.
Dr. Adams received his undergraduate degree in 1977 from McGill University and doctorate degree in 1981 from Massachusetts Institute of Technology.